Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Oct 25, 2025, 10:13Meet the 2025 WSO Award Winners for Their Extensive Contributions to Stroke Science
-
Oct 25, 2025, 09:53Aakanksha A Shares The 1st Post in ASH 12-Part Microlearning Series
-
Oct 25, 2025, 09:22Alessandro Bufi Presented SAIDE Project at World Stroke Congress 2025
-
Oct 25, 2025, 09:06A Short Story About a Platelet Named Pippa from Krista Goerger
-
Oct 25, 2025, 08:31Maxime Dely: What if We Could Leukoreduce Without a Filter?
-
Oct 24, 2025, 12:08Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
-
Oct 24, 2025, 12:03Melissa Glasner on Integration of Gene Therapy Into Hemophilia Care
-
Oct 24, 2025, 11:41Yaping Zhang on Platelet Adhesion Receptors
-
Oct 24, 2025, 11:37Omid Jafari and Colleagues Present the VTE-BERT Natural Language Processing Model
-
Oct 24, 2025, 11:34Insights on IV Thrombolysis and Mechanical Thrombectomy from Benjamin Maier and Colleagues
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 25, 2025, 09:32Sylaja Pn Wins 2025 WSO Presidential Award
-
Oct 25, 2025, 08:21Courtney Lawrence: Listen. Empower. Deliver. Save Lives!
-
Oct 25, 2025, 08:14Hema Tallman on Incredible Opportunity to Participate in the PPTA 2025 Meetings
-
Oct 24, 2025, 11:28Louise Bannon and Thomas Reiser Thank World Thrombosis Day Supporters Around The World
-
Oct 24, 2025, 10:48Melanie Daniel Congratulates Mickael Rosa and Antoine Rauch on Winning Bernd R. Binder Prize